
Opinion|Videos|October 21, 2024
Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging
Author(s)Neal Shore, MD, FACS
Key Takeaways
Neal Shore, MD, FACS, discusses the evolving use of follow-up PSMA PET scans and the recent FORE trial, which showed that Lutetium-177 improves radiographic progression-free survival and PSA levels in prechemotherapy patients with mCRPC, with more data on overall survival and quality of life expected.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Clinical Application of MMAI Score in Patients with Prostate Cancer
2
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Kevin Zorn, MD, on selecting among different MIST options for BPH
5







